Zagars Gunar K, Ballo Matthew T, Pisters Peter W T, Pollock Raphael E, Patel Shreyaskumar R, Benjamin Robert S
Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):739-47. doi: 10.1016/s0360-3016(03)00714-4.
To document the prognostic factors for survival of patients with soft-tissue sarcoma sustaining a first relapse after definitive treatment.
The clinicopathologic features, relapse patterns, and disease-specific survival rates for 402 consecutive patients sustaining a first relapse of sarcoma after combined surgery and radiotherapy were retrospectively reviewed. Factors affecting disease-specific survival after relapse were evaluated with univariate and multivariate techniques.
The median follow-up after relapse was 6.8 years. The overall disease-specific survival rate was 25%, 19%, and 16% at 5, 10, and 15 years, respectively, after the first relapse. The median survival duration was 21 months. Patients with an isolated local recurrence had a 5- and 10-year disease-specific survival rate of 48% and 46%, respectively, and those with an initial metastatic relapse had a disease-specific survival rate of 16% and 10%, respectively (p < 0.001). For isolated local recurrences, the independent determinants of survival were (favorable feature first) the primary tumor site (extremity and superficial trunk vs. head and neck and deep trunk); tumor grade (low and intermediate vs. high); time to recurrence (>12 vs. <or =12 months); and initial tumor size (<or =5 vs. >5 cm). Although the development of subsequent metastasis was the major cause of death, a significant fraction of patients died of uncontrolled primary tumor. For patients presenting with metastasis as the first relapse, the time to metastasis was the major determinant of survival (>12 vs. < or =12 months). Long-term salvage was largely confined to patients who could and did undergo resection of relapsed disease, either local or metastatic.
On the whole, patients whose sarcoma relapses fare poorly. However, select subgroups are potentially salvageable. Patients with an isolated local recurrence at sites other than the head and neck and deep trunk have a reasonable prospect for satisfactory outcome. Surgical resection of recurrences and metastases appears to play a major role in potential salvage.
记录接受确定性治疗后首次复发的软组织肉瘤患者的生存预后因素。
回顾性分析402例接受手术联合放疗后首次复发的肉瘤患者的临床病理特征、复发模式及疾病特异性生存率。采用单因素和多因素技术评估复发后影响疾病特异性生存的因素。
复发后的中位随访时间为6.8年。首次复发后5年、10年和15年的总体疾病特异性生存率分别为25%、19%和16%。中位生存时间为21个月。孤立性局部复发患者的5年和10年疾病特异性生存率分别为48%和46%,初始发生远处转移复发的患者疾病特异性生存率分别为16%和10%(p<0.001)。对于孤立性局部复发,生存的独立决定因素(有利特征优先)为原发肿瘤部位(四肢和浅躯干与头颈部和深躯干);肿瘤分级(低和中级与高级);复发时间(>12个月与≤12个月);以及初始肿瘤大小(≤5 cm与>5 cm)。尽管随后发生转移是主要死亡原因,但相当一部分患者死于原发肿瘤未得到控制。对于以转移作为首次复发表现的患者,转移时间是生存的主要决定因素(>12个月与≤12个月)。长期挽救主要局限于能够且确实接受了复发疾病切除(局部或远处)的患者。
总体而言,肉瘤复发的患者预后较差。然而,部分亚组患者有可能得到挽救。头颈部和深躯干以外部位发生孤立性局部复发的患者有获得满意结局的合理前景。复发和转移灶的手术切除似乎在潜在挽救中起主要作用。